
Pharmacelera
Computer-aided drug design company developing disruptive computational chemistry solutions.
- B2B
- saas
- subscription
- health
- enterprise software
- pharmaceutical
- biotechnology
- artificial intelligence
- 3d technology
- deep tech
- quantum technologies
- biotechnology
- horizon europe
- dt and ls
- spinout
- biotech and pharma
- core ai
- ai applications
- drug development
- nif defense security and resilience
- ai drug discovery
- research and development
- techbio
- seal of excellence ec
- chemistry
- digital pharma
- 4yfn 2025
- techbio drug discovery
- quantum computing
- nif protection of critical infrastructure
- compbio
- nif quantum
- quantum computing software
- biochemical
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor investor investor investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | €600k | Grant | |
Total Funding | 000k |
EUR | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | 140 % | (57 %) | 1426 % | - | - |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (913 %) | (210 %) | (2499 %) | (72 %) | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (428 %) | 54 % | (1631 %) | (66 %) | - | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Pharmacelera is a cutting-edge startup specializing in Computer Aided Drug Design (CADD) software and services. The company leverages advanced technologies like quantum mechanics and machine learning to explore a larger and more diverse chemical space, which is crucial for drug discovery. Pharmacelera's primary clients include pharmaceutical companies, biotech firms, and academic research institutions engaged in drug development.
Operating in the pharmaceutical and biotechnology markets, Pharmacelera offers a range of multi-platform software solutions and tailored services. Their proprietary algorithms and 3D hydrophobic descriptors provide more accurate molecular representations, enhancing the drug discovery process. These tools help clients identify new chemical compounds that could lead to the development of new medications, particularly in challenging areas like Central Nervous System (CNS) disorders.
Pharmacelera's business model revolves around flexible licensing of their software and offering bespoke services for drug discovery projects. They generate revenue through software licenses, service contracts, and consulting fees. By providing both ready-to-use software and customized solutions, they cater to a wide range of needs in the drug discovery pipeline.
In summary, Pharmacelera is at the forefront of computational chemistry, offering innovative tools and services that help pharmaceutical and biotech companies discover new drugs more efficiently and effectively.
Keywords: Drug Discovery, CADD, Quantum Mechanics, Machine Learning, Pharmaceutical, Biotech, Software, Licensing, CNS Disorders, Computational Chemistry.